Literature DB >> 12853794

Expectant management of small, recurrent, noninvasive papillary bladder tumors.

Mark S Soloway1, Darren S Bruck, Sandy S Kim.   

Abstract

PURPOSE: The majority of patients with stage Ta or T1 bladder cancer will have a subsequent tumor. Many of these patients invariably undergo multiple transurethral resections to manage small subsequent tumors or recurrences. We report our experience monitoring patients whose subsequent tumors appear to be small, low grade and papillary.
MATERIALS AND METHODS: A total of 32 patients with small, papillary, low grade appearing tumors and a history of Ta or T1 transitional cell carcinoma were monitored. The decision to delay resection or fulguration and observe these tumors was based on bladder cancer history, endoscopic appearance of the tumor and presence or lack of symptoms. All patients had a previous Ta tumor, and the tumor being observed was always papillary and appeared to be low grade. The decision to resect the tumor(s) was based on change in appearance (size or configuration) at followup endoscopy or hematuria. Patient records were reviewed, and bladder cancer history and tumor observation periods were recorded. Several patients underwent a number of observation periods. Tumor grade and stage before the observation interval were compared to the pathology of the observed tumor(s) after eventual resection. Tumor growth rate was calculated based on estimated tumor size documented at each interval.
RESULTS: Mean patient age was 72 years (range 39 to 88). Mean time since diagnosis of bladder cancer (initial urothelial tumor event) was 71 months (range 12 to 139). Mean number of subsequent tumor episodes or recurrences per patient was 3.8 (range 1 to 10). Mean number of transurethral resections was 3.8. Mean tumor-free interval before development of a subsequent tumor or mean time to recurrence was 13.4 months based on 104 tumor episodes. Not all tumor recurrences were observed. Mean number of tumor observation periods per patient was 1.8 (range 1 to 5) with a mean duration of 10.09 months per period based on 56 observation intervals. Mean time since the beginning of the initial observation period was 38 months (range 6 to 126). Mean tumor growth rate for 37 tumors was 1.77 mm per month (range 0 to 5.8). Only 3 of 45 (6.7%) patients had tumor progression from a pre-observation, low grade, noninvasive (TaG1 to 2) to a high grade Ta or T1 tumor. In the 3 observation periods in which the patient's most recent tumor was T1, 2 (67%) patients had TaG1 on resection after observation. Every patient with a T1 tumor before observation of a small new tumor had a history of a Ta tumor. No disease progressed to muscle invasion.
CONCLUSIONS: Small, recurrent, low grade appearing bladder tumors are slow growing and pose minimal risk. Therefore, as an alternative to in office fulguration to minimize morbidity and cost associated with repeat transurethral resection it may not be necessary to remove these tumors promptly at new tumor occurrence or recurrence.

Entities:  

Mesh:

Year:  2003        PMID: 12853794     DOI: 10.1097/01.ju.0000076621.71247.6c

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  35 in total

1.  Analysis of the Distribution and Temporal Trends of Grade and Stage in Urothelial Bladder Cancer in Northern New England from 1994 to 2004.

Authors:  Alan R Schned; Petra Lenz; Lee E Moore; Alison Johnson; Michael Jones; Masatoshi Kida; Debra T Silverman; Molly Schwenn; Karl T Kelsey; Angeline S Andrew; Dalsu Baris; Margaret R Karagas
Journal:  ISRN Pathol       Date:  2012

2.  Impact of 2004 ISUP/WHO classification on bladder cancer grading.

Authors:  Soum D Lokeshwar; Roberto Ruiz-Cordero; Marie C Hupe; Merce Jorda; Mark S Soloway
Journal:  World J Urol       Date:  2015-04-02       Impact factor: 4.226

Review 3.  [Photodynamic diagnostics of bladder carcinoma].

Authors:  F Vom Dorp; S Tschirdewahn; T Olbricht; T Szarvas; H Rübben
Journal:  Urologe A       Date:  2011-09       Impact factor: 0.639

4.  A Festschrift in Honor of Edward M. Messing, MD, FACS.

Authors:  Jean V Joseph; Ralph Brasacchio; Chunkit Fung; Jay Reeder; Kevin Bylund; Deepak Sahasrabudhe; Shu Yuan Yeh; Ahmed Ghazi; Patrick Fultz; Deborah Rubens; Guan Wu; Eric Singer; Edward Schwarz; Supriya Mohile; James Mohler; Dan Theodorescu; Yi Fen Lee; Paul Okunieff; David McConkey; Hani Rashid; Chawnshang Chang; Yves Fradet; Khurshid Guru; Janet Kukreja; Gerald Sufrin; Yair Lotan; Howard Bailey; Katia Noyes; Seymour Schwartz; Kathy Rideout; Gennady Bratslavsky; Steven C Campbell; Ithaar Derweesh; Per-Anders Abrahamsson; Mark Soloway; Leonard Gomella; Dragan Golijanin; Robert Svatek; Thomas Frye; Seth Lerner; Ganesh Palapattu; George Wilding; Michael Droller; Donald Trump
Journal:  Bladder Cancer       Date:  2018-10-03

Review 5.  Expectant Management of Low-Risk Bladder Cancer.

Authors:  Zachary L Smith; Mark S Soloway
Journal:  Curr Urol Rep       Date:  2015-12       Impact factor: 3.092

Review 6.  [Diagnostics of nonmuscle-invasive urothelial cell carcinoma of the bladder].

Authors:  S Tschirdewahn; F Vom Dorp
Journal:  Urologe A       Date:  2015-04       Impact factor: 0.639

7.  NCCN Guidelines Insights: Bladder Cancer, Version 2.2016.

Authors:  Peter E Clark; Philippe E Spiess; Neeraj Agarwal; Rick Bangs; Stephen A Boorjian; Mark K Buyyounouski; Jason A Efstathiou; Thomas W Flaig; Terence Friedlander; Richard E Greenberg; Khurshid A Guru; Noah Hahn; Harry W Herr; Christopher Hoimes; Brant A Inman; A Karim Kader; Adam S Kibel; Timothy M Kuzel; Subodh M Lele; Joshua J Meeks; Jeff Michalski; Jeffrey S Montgomery; Lance C Pagliaro; Sumanta K Pal; Anthony Patterson; Daniel Petrylak; Elizabeth R Plimack; Kamal S Pohar; Michael P Porter; Wade J Sexton; Arlene O Siefker-Radtke; Guru Sonpavde; Jonathan Tward; Geoffrey Wile; Mary A Dwyer; Courtney Smith
Journal:  J Natl Compr Canc Netw       Date:  2016-10       Impact factor: 11.908

Review 8.  High-risk non-muscle-invasive bladder cancer: update for a better identification and treatment.

Authors:  Oscar Rodriguez Faba; Joan Palou; Alberto Breda; H Villavicencio
Journal:  World J Urol       Date:  2012-10-16       Impact factor: 4.226

Review 9.  Natural biology and management of nonmuscle invasive bladder cancer.

Authors:  Kristen R Scarpato; Mark D Tyson; Peter E Clark
Journal:  Curr Opin Oncol       Date:  2016-05       Impact factor: 3.645

Review 10.  Approaching the optimal transurethral resection of a bladder tumor.

Authors:  Michael Jurewicz; Mark S Soloway
Journal:  Turk J Urol       Date:  2014-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.